Binding and Adsorption

1. What This Mechanism of Action Is

Binding and adsorption describe the ability of certain substances to physically or chemically bind other molecules—either through complex formation, ion exchange, or van der Waals forces. In the gut, this process can bind and eliminate heavy metals, mycotoxins, or excess bile acids before they exert systemic effects. In tissues, binding may neutralise inflammatory mediators or toxic metabolites. The mechanism is often non-specific, which presents both advantages (a broad spectrum of action) and disadvantages (potential interactions with nutrients). Binding affinity depends on factors such as pH, molecular size, and charge.

This mechanism is difficult to measure directly in humans, as binding typically occurs in the intestinal lumen or intracellularly. Indirect markers, such as the excretion of bound substances in stool or changes in laboratory parameters (e.g., blood heavy metal levels), are possible but susceptible to confounding factors. Controlled studies often require invasive methods or specialised tracers, which limits feasibility. While animal and cell studies provide mechanistic insights, they are not always translatable to humans.

2. Substances That Share This Mechanism

All substances in the database for which this mechanism of action is described—ranked by the extent of human testing. The numbers represent studies per type of investigation.

3. How Robust This Evidence Is

Mineral binders such as zeolite and bentonite are well supported, particularly by animal studies and laboratory findings. Zinc, green tea (EGCG), and milk thistle (silymarin) also demonstrate initial clinical effects in controlled human studies, such as the binding of heavy metals or the modulation of bile acids. Humic acid complexes have the highest number of laboratory and animal studies, while controlled human trials are lacking. Substances like turmeric, magnesium, or the gut microbiome are primarily documented through observational studies or cell-based experiments, but with limited evidence from controlled trials.

Many substances share similar binding mechanisms, such as chelation in the case of zinc and humic acid complexes or the adsorption of mycotoxins by mineral binders. While extrapolation from laboratory or animal findings to humans is plausible, it is not definitive. For example, humic acid complexes may bind mycotoxins similarly to zeolite, but clinical data are lacking. The combination of substances (e.g., zinc with EGCG) also shows promise in vitro but has scarcely been tested in humans. Additionally, non-specific binding raises questions about the bioavailability of nutrients.

4. Key Human Studies

• 1 The Zinc Paradox in Tuberculosis: A Systematic Review of Anti-Tuberculosis Drug–Induced Zinc Depletion and Its Implications for Optic Neuropathy and V (2026) — Zinc
• 2 Randomised clinical trial: does using zinc and zinc ionophore EGCG as supplements improve the outcome of active pulmonary tuberculosis (2021) — Zinc
• 3 Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations (2019) — Zinc
• 4 A randomised placebo-controlled clinical trial of oral green tea epigallocatechin 3-gallate on erythropoiesis and oxidative stress in transfusion-dependent (2023) — Green Tea and EGCG
• 5 Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassaemia (2024) — Green Tea and EGCG
• 6 Gel Containing Catechin and Mesoporous Silica Nanoparticles for Protecting Root Dentin Against Erosion: An In Situ Study (2025) — Green Tea and EGCG
• 7 Silymarin for adults with metabolic dysfunction-associated steatotic liver disease (2025) — Milk Thistle (Silymarin)
• 8 Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassaemia patients: a systematic review and meta-analysis for effect on (2021) — Milk Thistle (Silymarin)
• 9 Silibinin Suppresses Tumour Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer (2021) — Milk Thistle (Silymarin)
• 10 Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhoea: A randomised controlled trial (2023) — Turmeric and Curcumin
• 11 Curcumin: from ancient medicine to current clinical trials (2008) — Turmeric and Curcumin
• 12 Therapeutic potential of curcumin in digestive diseases (2013) — Turmeric and Curcumin
• 13 Prevention of hypomagnesaemia in critically ill patients with acute kidney injury on continuous kidney replacement therapy: the role of early supplementation (2021) — Magnesium
• 14 Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review (2023) — Magnesium
• 15 The Impact of Regional Citrate Anticoagulation on Magnesium Replacement During CRRT (2023) — Magnesium
• 16 Novel treatments for Parkinson's disease (2026) — Gut microbiome
• 17 Single-cell viral tagging of Faecalibacterium prausnitzii reveals rare bacteriophages missed by other techniques (2025) — Gut microbiome
• 18 Commensal dysbiosis alters primary bile acid signalling to drive mammary gland inflammation and breast tumour dissemination (2026) — Gut microbiome
• 19 Unravelling the connection: visceral adipose tissue and vitamin D levels in obesity (2023) — Vitamin D
• 20 Impact of BMI on serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with calcifediol supplementation in young adults: a longitudinal study (2024) — Vitamin D
• 21 Impact of SNP variants in PON-1 or UGT1A1 on iron chelation therapy outcomes and zinc status in patients with thalassaemia major (2026) — Vitamin D
• 22 Adaptive function of soil consumption: an in vitro study modelling the human stomach and small intestine (2004) — Mineral binders (zeolite, bentonite)
• 23 Pharmacological agents for chronic diarrhoea (2015) — Mineral binders (zeolite, bentonite)
• 24 A high-capacity bentonite clay for the sorption of aflatoxins (2020) — Mineral binders (zeolite, bentonite)

5. Open Questions

• Humic acid complexes: Are there clinically relevant binding affinities for heavy metals or mycotoxins in humans, and how does this affect nutrient absorption?
• Combination therapies: Can synergistic effects (e.g., zinc + EGCG) be demonstrated in controlled human studies without impairing the bioavailability of essential minerals?
• Long-term effects: What are the impacts of chronic intake of binders (e.g., mineral substances, humic acid complexes) on the gut microbiome or the liver’s detoxification capacity?
• Specificity: Can binders be optimised for specific toxins without simultaneously binding beneficial substances (e.g., vitamins, trace elements)?
• Tissue adsorption: Can mechanisms of intracellular binding (e.g., of inflammatory mediators) be demonstrated in humans, and what would be the clinical consequences?

See also the gaps list for all substances. This page is recalculated with each update.